Home >> Current Medical Research and Opinion, Volume 22, Number 11

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension

Authors: Palmer, Andrew J.1; Valentine, William J.1; Tucker, Daniel M.D.1; Ray, Joshua A.1; Roze, Stéphane1; Annemans, Lieven2; Lapuerta, Pablo3; Chen, Roland3; Gabriel, Sylvie4; Carita, Paulo4; Rodby, Roger A.5; de Zeeuw, Dick6; Parving, Hans-Henrik7; Laville, Maurice8

Source: Current Medical Research and Opinion, Volume 22, Number 11, November 2006 , pp. 2095-2100(6)

Publisher: Informa Healthcare

Buy & download fulltext article:

OR

Price: $51.50 plus tax (Refund Policy)

Abstract:

Objectives: We performed a cost-consequence analysis in a French setting of the renoprotective benefit of irbesartan in hypertensive type 2 diabetes patients over a 25-year period.

Research design and methods: A previously published Markov model simulated progression from microalbuminuria to overt nephropathy, doubling of serum creatinine, end-stage renal disease and death. Three treatment strategies with analogous blood pressure control were compared: (A) control - conventionally medicated antihypertensive therapy (excluding angiotensin converting enzyme inhibitors, other angiotensin-2-receptor antagonists and dihydropyridine calcium channel blockers) initiated at microalbuminuria; (B) early irbesartan - (300 mg daily added to control, initiated with microalbuminuria) and (C) late irbesartan - (300 mg daily, initiated with overt nephropathy). Probabilities came from the Irbesartan in Reduction of Microalbuminuria-2 study, Irbesartan in Diabetic Nephropathy Trial and other sources. Clinical and economic outcomes were projected over 25 years. Annual discount rates were 3%.

Results: Compared to control, early use of irbesartan added (mean ± standard deviation) 1.51 ± 0.08 undiscounted life years (discounted: 0.94 ± 0.05 years), while late irbesartan added 0.07 ± 0.01 (0.04 ± 0.01) years/patient. Early irbesartan added 1.03 ± 0.06 discounted quality-adjusted life years (QALYs), while late irbesartan added 0.06 ± 0.01 QALYs. Early and late irbesartan treatments were projected to save €22 314 ± 1273 and €6619 ± 820/patient, respectively versus control. Sensitivity analysis showed that even over short time horizons both irbesartan treatments were superior to the control group.

Conclusions: In France, early irbesartan treatment improved quality and length of life and reduced costs in hypertensive patients with type 2 diabetes and microalbuminuria. Late irbesartan therapy is beneficial, but earlier irbesartan leads to better outcomes.

Keywords: COSTS; DIABETES; FRANCE; HYPERTENSION; IRBESARTAN; NEPHROPATHY

Document Type: Case report

DOI: http://dx.doi.org/10.1185/030079906X132730

Affiliations: 1: CORE - Center for Outcomes Research, Allschwil/Basel, Switzerland 2: IMS-HEDM, Meise, Belgium; Ghent University, Ghent, Belgium 3: Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ, USA 4: Sanofi-Aventis, Bagneux, France 5: Rush University Medical Center, Chicago, USA 6: Department of Clinical Pharmacology, University Medical Center, Groningen, the Netherlands 7: Steno Diabetes Center, Gentofte, Denmark 8: Department of Nephrology, Edouard Herriot Hospital, Lyon, France

Publication date: 2006-11-01

More about this publication?
Marked list

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
^ Back to top
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page